Riskpilot← Back to searchSign inGet full accessNATURAMED PHARMA AS
ASActiveOrg 970980016Vinkelveien 2, 3027 DrammenPostordre-/Internetthandel med helsekost · NACE 47917Est. 19940 employeeswww.naturamed-pharma.no
Revenue 2021
NOK 55,6M
-2% vs 2020
EBITDA margin
10.1%
-5% vs 2020
Equity ratio
52.8%
Financial strength
Net profit 2021
NOK 3,8M
-5% vs 2020
| Revenue | NOK 55,6M | -2% |
| EBITDA | NOK 5,6M | -5% |
| Net profit | NOK 3,8M | -5% |
| Total assets | NOK 35,9M | +41% |
| Equity | NOK 18,9M | +25% |
| Employees | 0 | — |
Legal name
NATURAMED PHARMA AS
Org number
970980016
Legal form
Aksjeselskap
NACE code
47917 · Postordre-/Internetthandel med helsekost
Founded
1. januar 1994
Share capital
NOK 554 052 600
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap.
Company purpose
Handel med helsekost og forlagsvirksomhet.
Address
Vinkelveien 2, 3027 Drammen
Phone
+4732216000
Email
post@naturamed-pharma.no
Website
www.naturamed-pharma.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 75 741 | 68 068 | 64 005 | 57 030 | 55 605 |
| Staff expenses | −17 464 | −18 046 | −17 239 | −18 804 | −15 793 |
| EBITDA | 4 902 | 12 347 | 8 298 | 5 911 | 5 605 |
| Depreciation & amort. | −513 | −558 | −463 | −249 | −358 |
| EBIT | 4 390 | 11 789 | 7 835 | 5 663 | 5 247 |
| Net financials | 222 | −71 | −88 | −240 | −292 |
| Profit before tax | 4 612 | 11 719 | 7 746 | 5 422 | 4 955 |
| Tax | 1 136 | 2 720 | −3 252 | 1 407 | 1 122 |
| Net profit | 3 476 | 8 998 | 11 494 | 4 016 | 3 833 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 22 294 | 30 724 | 40 898 | 25 403 | 35 884 |
| Equity | 10 953 | 19 733 | 31 134 | 15 104 | 18 932 |
| Long-term debt | 17 | 34 | 61 | 8 | 10 140 |
| Short-term debt | 11 324 | 10 956 | 9 703 | 10 292 | 6 812 |
| Total debt | 11 341 | 10 991 | 9 764 | 10 299 | 16 952 |
EBITDA margin
10.1%
This company
15.8%
Market median
-36% vs market
20172021
Equity ratio
52.8%
This company
38.2%
Market median
+38% vs market
20172021
Return on equity
20.2%
This company
18.4%
Market median
+10% vs market
20172021
Net profit margin
6.9%
This company
8.1%
Market median
-15% vs market
20172021
Asset turnover
1.55×
This company
1.12×
Market median
+38% vs market
20172021
Debt / equity
0.90×
This company
0.62×
Market median
+45% vs market
20172021
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AR Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Former (1) | ||
| Chairman | 2020 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of NATURAMED PHARMA AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Aleksander Rikard Storvestre | Chief Executive Officer | 0 companies |
| Bodil Johanne Lien Arnesen | Chairman | 0 companies |
| Bernard Jean Y Lemaire | Chairman | 0 companies |
| Frode Kåsin | Board of Directors | 0 companies |